Pricing Pressure, Patent Cliffs, and Shifting Patient Expectations: What Pharma Marketers Need to Rethink Right Now

We Are Not in a Transition Period. This Is the New Normal.

Every few years, someone in the pharmaceutical industry declares that we are entering a new era of commercial complexity. This time, I believe it is genuinely true. The combination of forces reshaping pharma marketing in 2026 is not cyclical. The Inflation Reduction Act's pricing negotiation framework, the accelerating biosimilar market, the growing sophistication of payer decision-making, and the shift in patient expectations toward transparency and engagement are structural changes, not temporary headwinds.

Patent protection on major blockbusters is eroding at scale, with more than USD 300 billion in sales at risk between 2026 and 2030. The IRA's first negotiated drug prices are now taking effect, compressing margins on established products. And the generation of patients and payers now driving purchasing decisions expects real-world evidence of value, not just phase three trial data. Commercial leaders who continue to build their strategies on legacy frameworks will find the gap between their expectations and their results growing wider every quarter.

The IRA Is a Commercial Strategy Problem, Not Just a Pricing Problem

I want to be direct about something I see consistently in conversations with pharma commercial teams: the IRA is being treated primarily as a finance and market access problem. It is not. It is a full commercial strategy problem. For small molecules on the market for seven or more years, and biologics on the market for eleven or more years, the revenue floor has fundamentally shifted. That shift has direct implications for how you structure your marketing investments, how you manage lifecycle planning, and how you frame the value story for your portfolio.

Early movers at companies like Eli Lilly, Pfizer, and Novo Nordisk are already building direct-to-consumer and patient services models that are designed to work within the new price structures. For mid-tier and specialty pharma companies, the implications are just as significant, and often less resourced to address. Marketing investments need to be evaluated against a new commercial reality. Lifecycle management strategies need to be front-loaded. Portfolio positioning needs to account for the therapeutic areas where pricing pressure is most acute: oncology, immunology, and cardiometabolic disease together represent over 83% of major biopharma R&D programs, and those are precisely the categories facing the most sustained payer scrutiny.

Biosimilar Competition Requires More Than a Defensive Posture

The biosimilars market is accelerating rapidly, and pharmaceutical companies are facing a genuine dual challenge. On one side, they are defending established biologic brands against growing biosimilar competition. On the other, many are simultaneously building out biosimilar portfolios of their own. Both strategies require disciplined brand positioning, and they require very different messaging architectures to execute well.

For originator biologics, the marketing priority is demonstrating differentiated value that biosimilar competitors cannot easily replicate, whether through delivery mechanism, patient support infrastructure, real-world adherence outcomes, or the prescriber confidence that comes from years of established clinical use. For biosimilar entrants, the challenge is earning the confidence of prescribers who remain cautious about switching and payers who need a total cost-of-care argument, not simply a price comparison.

I have seen too many companies try to manage both sides of this challenge with the same marketing team, the same messaging framework, and the same budget allocation. That rarely works. Both strategies require dedicated investment in medical education, evidence-based content, and stakeholder engagement programs that reach the right decision-makers at the right points in their evaluation process.

Moving from Omnichannel Strategy to Omnichannel Orchestration

The distinction between omnichannel strategy and omnichannel orchestration is one that I find increasingly important in conversations with pharma commercial leaders. Strategy tells you which channels to use and why. Orchestration determines how every touchpoint across your HCP engagement programs, patient education initiatives, payer communication, and medical affairs work together as a coherent and measurable system. The challenge for most pharma organisations is not a shortage of channels. It is the disconnected workflow between them.

Marketers who can build integrated engagement architectures, connect data sources across commercial functions, and deliver consistent value evidence at every touchpoint will have a real structural advantage in the current environment. That is not about having more data. It is about having the right data framework, the analytical capability to generate meaningful insight from it, and the content infrastructure to act on those insights at scale and with speed.

What Pharmaceutical Brands Built for the Long Term Look Like

The pharmaceutical and biopharma brands generating the strongest commercial trajectories in 2026 are not simply better funded or better resourced than their competitors. They make deliberate decisions about where to invest their commercial energy. They build medical and scientific credibility as a foundation, not an afterthought. They align patient engagement and payer access strategies so they reinforce rather than contradict each other. They treat their digital and content infrastructure as long-term commercial assets. And they work with external partners who understand both the regulatory parameters of pharmaceutical marketing and the strategic and creative disciplines required to make it work.

At VELLUM, we help pharmaceutical and biopharma companies build marketing strategies that are grounded in science, shaped by market access intelligence, and designed to perform across the full commercial lifecycle, from pre-launch brand building through to loss-of-exclusivity planning.

Preparing for a major launch or navigating a portfolio transition? Book a consultation with VELLUM.

About VELLUM Global

VELLUM is a life sciences-focused marketing agency serving companies across Medical Devices & Diagnostics, Pharmaceuticals & Biologics, OTC & Consumer Health, Cosmetics & Specialty Chemicals, Food & Nutritional Supplements, Laboratory Equipment & Scientific Instruments, CDMOs & Manufacturing Organizations, and Regulatory & Consulting Organizations. We combine strategic intelligence, scientific credibility, and marketing craft to help our clients build meaningful brands, generate qualified leads, and grow commercially in one of the world's most consequential industries.